Tier 2 — strong

Dietary antioxidant supplementation combined with quercetin improves cycling time trial performance

Holden S H MacRae, Kari M Mefferd
International journal of sport nutrition and exercise metabolism 2006 16(4):405

Bibliography

PubMed
PMID 17136942
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind crossover cycling study
ModelHuman intervention research
Sample11 elite male cyclists
InterventionAntioxidant vitamin formulation with quercetin versus the formulation without quercetin
Duration6 weeks
EndpointsExercise performance or recovery

What the study showed, in plain terms

Published in 2006, this source examined exercise and recovery. Design: Randomized double-blind crossover cycling study. Sample/model: 11 elite male cyclists. The exposure or intervention was Antioxidant vitamin formulation with quercetin versus the formulation without quercetin. Follow-up or treatment period: 6 weeks.

The quercetin-containing formulation improved cycling time relative to baseline.

The abstract emphasizes a baseline comparison rather than a clear direct between-formulation effect. Small sample and multiple ingredients limit attribution.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Exercise: Performance, Recovery and Muscle. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The quercetin-containing formulation improved cycling time relative to baseline.
  • The recorded outcome domains were Exercise performance or recovery.
  • The result applies to the tested exposure: Antioxidant vitamin formulation with quercetin versus the formulation without quercetin; 6 weeks.

What this study can and cannot tell us

  • The abstract emphasizes a baseline comparison rather than a clear direct between-formulation effect. Small sample and multiple ingredients limit attribution.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified